Mapi Pharma is a clinical stage pharmaceutical company that develops complex active pharmaceutical ingredients and proprietary pharmaceuticals, including long acting depot injectable drugs.

Mapi Pharma

Mylan N.V. was a global generic and specialty pharmaceuticals company that developed and produced medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women's healthcare. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris.

Mylan N.V.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Kyung Ae Lee

Thomas A Wynn

Christina Warren

Pfizer Inc.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Metric
Company Name	Mapi Pharma	Mylan N.V.	Pfizer Inc.	Immunocore Holdings plc
Symbol			PFE	IMCR
MSH ID	COM:MAPI-PHARMA	COM:MYLAN	COM:PFIZER	COM:IMMUNOCORE
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare
Industry	Pharmaceuticals	Pharmaceuticals	Drug Manufacturers - General	Biotechnology
Country	IL		US	GB
Stage	Corporate Round
Employee Count			88K	497
Website	mapi-pharma.com	mylan.com	pfizer.com	immunocore.com
LinkedIn			pfizer	immunocore
Founders

Metric
Market Cap		160.65B	1.90B
Enterprise Value
Monthly Web Traffic	612	1.84M	6.81K
Web Traffic Growth		0.15	-0.38
Valuation
Raised Capital	20M	1B	350M

Metric
Revenue	58.50B	249.43M
Revenue (LTM)
Revenue (NTM)
Gross Profit	29.28B	248.39M
EBITDA	10.53B	-38.47M
Operating Income	4.24B	-59.65M
Net Income	2.12B	-55.29M
EPS	0.38	-0.00
Diluted EPS	0.38	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.52	1.00
Operating Profit Margin	0.06	-0.22
EBITDA Margin	0.18	-0.15
Net Profit Margin	0.04	-0.19
Return on Equity	0.02	-0.17
Return on Assets	0.01	-0.06
Return on Capital Employed	5.56	-0.08

MAPI

COM:MAPI-PHARMA

Mapi Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	14.35	-53.27
P/B Ratio	1.55	9.88
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.21	9.95
EV Multiple	17.74	-46.28

Metric
Days Sales Outstanding	79.90	94.90
Days Payables Outstanding	72.06	2.93K
Days Inventory Outstanding	155.46	1.58K
Operating Cycle	230.19	1.67K
Cash Conversion Cycle	160.85	-2.98K
Asset Turnover	141.27	0.42

Metric
Operating Cash Flow	8.70B	2.94M
Free Cash Flow	4.79B	-2.48M
Cash Flow to Debt	0.12	0.04
Operating Cash Flow/Sales	0.16	0.05
Free Cash Flow Yield	0.05	0.00

Metric
Cash & Equivalents	2.85B	442.63M
Accounts Receivable	347M	-17.87M
Inventory	10.19B	4.50M
Goodwill	67.78B
Debt to Capitalization	0.45	0.57
Debt to Assets	0.30	0.15
Current Ratio	2.38	4.26
Quick Ratio	94.70	5.94

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.14
R&D to Revenue	0.17	0.60
SG&A to Revenue		0.24